BioCentury | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

...Before joining Axcella last year, King-Jones was lead commercial counsel at Sarepta Therapeutics Inc. (NASDAQ:SRPT). NervGen Pharma Corp....
...Inc. Elizabeth S. Eaton, Staff Writer Ultragenyx Pharmaceutical Inc. MiMedx Group Inc. Iveric bio Inc. Agios Pharmaceuticals Inc. Ardelyx Inc. Axcella Health Inc. NervGen Pharma Corp. Novo...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...3/27/19 $173.0 $371.9 $565.8 52% BioLASCO Taiwan Co. Ltd. (TPEx:6662) 3/26/19 $2.5 $30.6 $35.7 17% NervGen Pharma Corp....
BioCentury | Mar 22, 2019
Financial News

Spinal cord injury company NervGen raises $10M IPO

...spinal cord injury and peripheral nerve injury and begin a Phase I trial in 2020. NervGen Pharma Corp....
...acute myocardial infarction (MI), multiple sclerosis, stroke and Alzheimer’s disease. Mary Romeo, Staff Writer Case Western Reserve University NervGen Pharma Corp. Jerry...
Items per page:
1 - 3 of 3
BioCentury | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

...Before joining Axcella last year, King-Jones was lead commercial counsel at Sarepta Therapeutics Inc. (NASDAQ:SRPT). NervGen Pharma Corp....
...Inc. Elizabeth S. Eaton, Staff Writer Ultragenyx Pharmaceutical Inc. MiMedx Group Inc. Iveric bio Inc. Agios Pharmaceuticals Inc. Ardelyx Inc. Axcella Health Inc. NervGen Pharma Corp. Novo...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...3/27/19 $173.0 $371.9 $565.8 52% BioLASCO Taiwan Co. Ltd. (TPEx:6662) 3/26/19 $2.5 $30.6 $35.7 17% NervGen Pharma Corp....
BioCentury | Mar 22, 2019
Financial News

Spinal cord injury company NervGen raises $10M IPO

...spinal cord injury and peripheral nerve injury and begin a Phase I trial in 2020. NervGen Pharma Corp....
...acute myocardial infarction (MI), multiple sclerosis, stroke and Alzheimer’s disease. Mary Romeo, Staff Writer Case Western Reserve University NervGen Pharma Corp. Jerry...
Items per page:
1 - 3 of 3